Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2/3 × Ependymoma × Etoposide × Clear all

Phase

Phase 2 7 Phase 1 3 Phase EARLY_PHASE1 1 Phase 3 1 Phase 2/3 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 7 Lymphoma 6 Lymphoma, Large B-Cell, Diffuse 5 Leukemia 5 Lymphoma, Non-Hodgkin 4 Recurrence 3 Sezary Syndrome 2 Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 2 Myelodysplastic Syndromes 2 Mycosis Fungoides 2 Lymphoma, T-Cell, Cutaneous 2 Lymphoma, Follicular 2 Leukemia, T-Cell 2 Leukemia, Myeloid, Acute 2 Leukemia, Biphenotypic, Acute 2 Waldenstrom Macroglobulinemia 1 Thrombocythemia, Essential 1 Small Cell Lung Carcinoma 1 Retinoblastoma 1 Primary Myelofibrosis 1 Polycythemia Vera 1 Neuroblastoma 1 Neoplasms 1 Myeloproliferative Disorders 1 Myelodysplastic-Myeloproliferative Diseases 1 Multiple Myeloma 1 Medulloblastoma 1 Lymphoma, Mantle-Cell 1 Lymphoma, Large-Cell, Immunoblastic 1 Lymphoma, Large-Cell, Anaplastic 1

Interventions

trofosfamide 1 Thiotepa 1 Temozolomide 1 Etoposide 1 Carboplatin 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT00749723 2018-07-20

HIT-REZ-2005

University Hospital, Bonn

Phase 2/3 Completed

Brain Neoplasms, Ependymoma, Medulloblastoma, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon ⚡